摘要
目的探讨131I二次治疗Graves甲亢对患者血清相关指标及甲减发生率的影响。方法选择2015年4月~2017年5月重庆市黔江中心医院收治的Graves甲状腺功能亢进症患者90例,根据随机数字表法分为对照组(45例)和研究组(45例)。对照组患者采用甲巯咪唑治疗,研究组患者采用131I治疗,两组患者连续治疗12个月。检测并比较两组治疗前后血清促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、甲状腺刺激抗体(TSAb)、甲状腺刺激阻断性抗体(TSBAb)及促甲状腺激素受体抗体(TRAb)水平。比较两组治疗后的甲状腺功能减退发生率。结果两组患者治疗前血清TSH、FT3、FT4、TSAb、TSBAb及TRAb水平之间的差异无统计学意义(P> 0.05);与治疗前比较,两组患者治疗后血清TSH水平明显升高(P <0.05),血清FT3、FT4、TSAb、TSBAb及TRAb水平均明显降低(P <0.05),而研究组患者治疗后血清TSH高于对照组(P <0.05),血清FT3、FT4、TSAb、TSBAb及TRAb水平低于对照组(P <0.05)。研究组治疗后的甲状腺功能减退发生率与对照组比较,差异无统计学意义(P> 0.05)。结论 131I二次治疗Graves甲亢能够明显改善血清TSH、FT3、FT4、TSAb、TSBAb及TRAb水平,其甲状腺功能减退发生率与甲巯咪唑治疗相比无明显差异。
Objective To investigate the effect of 131I second treatment on se rum related indexes and hypothyroidism rates in the treatment of Graves disease. Methods From April 2015 to May 2017, 90 patients with Graves disease treated in Chongqing Qianjiang Central Hospital were selected, according to the random number table method, they were divided into control group(n=45) and study group(n=45). The patients in the control group were treated with Methamazole, while the patients in the research group were treated with 131I. The patients of two groups were treated for 12 months. The serum thyroid stimulating hormone(TSH), free triiodothyronine(FT3), free thyroxine(FT4), thyroid stimulating an body(TSAb), thyroid stimulation-blocking antibody(TSBAb) and thyrotrophin receptor antibody(TRAb) of the two groups before and after treatment was compared. The hypothyroidism rates of the two groups after treatment was compared. Results There was no significant difference of the serum levels of TSH, FT3, FT4, TSAb, TSBAb and TRAb in the two groups before treatment(P > 0.05). After treatment, the serum TSH of the two groups was significantly higher than before treatment, the serum levels of FT3, FT4, TSAb, TSBAb and TRAb of the two groups were significantly lower than before treatment(P < 0.05);and the levels of serum TSH was higher than the control group after treatment, the levels of serum FT3, FT4, TSAb, TSBAb and TRAb in the study group were lower than the control group after treatment(P < 0.05). There was no significant difference in the incidence of hypothyroidism between the two groups after treatment(P > 0.05). Conclusion 131I in the second treatment of Graves disease can improve the serum levels of TSH, FT3, FT4, TSAb, TSBAb and TRAb, and the hypothyroidism rate between the 131I and Methamazole has no difference.
作者
陈正萍
易吉秀
凌冰
赵莉
蒲银燕
CHEN Zhengping;YI Jixiu;LING Bing;ZHAO Li;PU Yinyan(Department of Pharmacy, Chongqing Qianjiang Central Hospital, Chongqing 409000, China;Department of Endocrine, Chongqing Qianjiang Central Hospital, Chongqing 409000, China)
出处
《中国医药导报》
CAS
2019年第18期61-64,共4页
China Medical Herald
基金
重庆市医学科研计划项目(20143030)
重庆市黔江区科技计划项目(黔科计2013078)
